PMD Psychemedics Corp.

Glancy Prongay & Murray Announces the Filing of a Securities Class Action on Behalf of Psychemedics Corporation Investors and Encourages Investors to Contact the Firm

Glancy Prongay & Murray LLP (“GPM”) announces that a class action lawsuit has been filed on behalf of investors who purchased Psychemedics Corporation (“Psychemedics” or the “Company”) (NASDAQ: PMD) securities between February 28, 2014 and January 30, 2017, inclusive (the “Class Period”). Psychemedics investors have until April 3, 2017 to file a lead plaintiff motion.

Investors suffering losses on their Psychemedics investments are encouraged to contact Lesley Portnoy of GPM to discuss their legal rights in this class action at 310-201-9150 or by email to [email protected].

The Complaint alleges that throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (1) through its affiliate Psychemedics Brasil Exames Toxicologicos Ltda., Psychemedics engaged in anticompetitive conduct to maintain a monopoly over the Brazilian market in violation of the law; (2) effectively, Psychemedics lacked effective internal controls over financial reporting; and (3) consequently, Psychemedics' public statements were materially false and misleading at all relevant times.

On January 31, 2017, news reports revealed that Psychemedics engaged in unlawful anticompetitive conduct in Brazil in order to stifle the business of its competitor Omega Laboratories, Inc. USA. Psychemedics allegedly used “cartel practices” to “form a drug testing monopoly which included unenforceable and exclusive contracts with collection sites, all with a view to limit the entry and operation of new companies in the market.”

On this news, shares of Psychemedics fell $6.75 per share, or over 26%, to close at $18.87 per share on January 31, 2017.

If you purchased shares of Psychemedics during the Class Period you may move the Court no later than April 3, 2017 to ask the Court to appoint you as lead plaintiff if you meet certain legal requirements. To be a member of the Class you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the Class. If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to [email protected], or visit our website at http://glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

EN
14/02/2017

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Psychemedics Corp.

 PRESS RELEASE

Psychemedics Releases 2025 Workforce Insights Report

Psychemedics Releases 2025 Workforce Insights Report Synthetic Drug Threats and Legalization Risks Shape a New Era for Workplace Safety DALLAS, June 16, 2025 (GLOBE NEWSWIRE) -- Psychemedics Corporation, a global leader in hair testing for drugs of abuse, today announced the release of its second annual Workforce Insights Report, providing a comprehensive look at the evolving drug landscape and its impact on workplace safety, hiring practices, and employer risk. The 2025 Psychemedics Insights Report draws from the largest proprietary database of hair drug testing results in the industr...

 PRESS RELEASE

Psychemedics Named “Most Innovative Drug Testing Company of the Year”

Psychemedics Named “Most Innovative Drug Testing Company of the Year” DALLAS, May 16, 2025 (GLOBE NEWSWIRE) -- Psychemedics Corporation, the world’s leading provider of hair drug testing, is proud to announce it has been named “Most Innovative Drug Testing Company of the Year” by Acquisition International Magazine as part of its prestigious 2025 Global Excellence Awards. This recognition honors Psychemedics’ continued leadership in advancing the science of drug detection, including the recent launch of its Enhanced Quartile Reporting. This breakthrough analytics tool provides deeper insi...

 PRESS RELEASE

Psychemedics Launches Groundbreaking Quartile Reporting for Enhanced D...

Psychemedics Launches Groundbreaking Quartile Reporting for Enhanced Drug Testing Insights DALLAS, March 03, 2025 (GLOBE NEWSWIRE) -- Psychemedics Corporation, a global leader in hair drug testing, is proud to announce the launch of its innovative Quartile Reporting feature. This industry-first enhancement empowers organizations with unprecedented insights into drug test results, enabling data-driven decision-making and fostering safer, more productive workplaces. The new Quartile Reporting feature allows clients to see where a candidate’s or employee’s test results fall within a range o...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: December 14, 2024

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

ResearchPool Subscriptions

Get the most out of your insights

Get in touch